美国(University of Kentucky)Sheng Tong教授招收生物医学工程2020级博士生

stong7301UID：4002179

1.招生类型
Ph.D., Fall 2020.

2.招收学校(单位)名称
F. Joseph Halcomb III, M.D. Department of Biomedical Engineering, University of Kentucky
The University of Kentucky is one of the few universities in the U.S. having a major academic medical center with six health sciences colleges including Medicine, Dentistry, Pharmacy, Nursing, Health Sciences, and Public Health, and a full spectrum of other academic colleges, all within walking distance of each other. The school of pharmacy and Markey cancer center at the University of Kentucky are highly ranked in US. The department of Biomedical Engineering is a new program in the college of engineering, but expanded rapidly in recent years. There are tremendous opportunities to work closely with the medical center. For candidates who desire to advance their career through true integration of engineering and medicine with clinical relevance, UK provides the right environment for them.

3.学制以及何种专业
Full time Ph.D. students in nanomedicine, genome editing and cancer immunotherapy (4~5 years).

4.        学校或单位地点
University of Kentucky is located at Lexington, Kentucky, USA

5.        提供的补助待遇
Full scholarship/research assistant

6.        导师(课题组)介绍
Our laboratory just started in Fall 2019 at the University of Kentucky. Our lab is dedicated to the development of cutting-edge technologies for disease treatment. Current projects include the following topics: nanobiotechnology, genome editing, immunoengineering, cancer immunotherapy and drug/gene delivery.

For more information, please visit http://nm.engr.uky.edu

7. 成绩要求
Minimum acceptable TOEFL score is 550 (paper-based) 213 (computer-based), or 79 (internet-based). The minimum IELTS score is 6.5.

Background in cell/molecular biology, molecular cloning, immunology are preferred.

8. 申请时间
Deadline: February 1st, 2019. Early application is strongly encouraged.
　
9. 联系方式
Please send your CV and transcripts to Prof. Sheng Tong (sheng.tong@uky.edu) for initial evaluation.